PRI heads into its August 5 earnings date with analysts upgrading their conviction and options traders positioned notably more bullish than usual.
The clearest signal this week came from the Street. TD Cowen raised its price target on Primerica from $322 to $360 on July 22 — today — while keeping its Buy rating, a move that puts one of the more optimistic analysts well above the consensus mean of $302. The gap matters: the stock closed at $309.53, meaning it has already passed the average Street target after a 10% gain over the past month. Keefe, Bruyette & Woods lifted its own target to $323 from $305 last week, though it stayed at Market Perform. Jefferies nudged its Hold target to $268 from $266 — barely moving, and well below the current price. The overall direction of travel is upward on targets, but the ratings tell a more cautious story: the three most active analysts on this name are all sitting at neutral or below, even as they chase the stock higher with their numbers. That tension — rising targets, unchanged cautious ratings — is worth noting ahead of the print.
Options traders are leaning decisively into the bullish side. The put/call ratio has dropped to 0.24, almost two standard deviations below its 20-day average of 0.28, placing it near the most call-heavy reading of the past year (the 52-week low PCR is 0.19). That's a meaningful tilt: for every put being bought, roughly four calls change hands. Whether that reflects conviction ahead of earnings or simple momentum-chasing after a strong month, the options market is not positioned for downside protection right now.
Short interest tells a quieter story. Bears hold about 3.6% of the free float — down roughly 3.5% on the week after a brief mid-July build that took it to just above 1.19 million shares. Borrowing conditions are close to frictionless: the cost to borrow eased to 0.36% this week, an 11% drop in seven days, and availability is at 4,667% — meaning lenders are sitting on roughly 47 shares available for every one currently borrowed. There is no squeeze pressure here, no borrow crunch forming, and no signal that the short community is building a meaningful thesis against the name. The ORTEX short score of 40.8 reflects that — middling, and drifting slightly lower through July.
On valuation, the stock's P/E has expanded by roughly a full point over the past 30 days to 12x, and price-to-book has risen 0.28 turns to 3.36x over the same period — a gentle but consistent re-rating as the price has climbed. The dividend score ranks in the 89th percentile against the broader universe, suggesting income characteristics the market continues to value. EPS surprise ranks in the 73rd percentile, consistent with a company that has managed to beat estimates with reasonable regularity. The forward earnings growth picture is thinner, ranking only in the 30th percentile on 12-month forward EPS growth — the bulls are betting on execution quality and distribution growth, not a step-change in earnings power. The bear case centers on an elevated P/E relative to insurance peers, slow recruitment risk, and residual questions from the Senior Health goodwill write-off, though that is a dated concern.
Institutional ownership is stable and concentrated: Kayne Anderson Rudnick holds nearly 10%, BlackRock 9.6%, and Fidelity 9.1%. Geode added 77,000 shares through June 30, and BlackRock added roughly 42,000. Insider activity has been light and directionally consistent with management monetizing prior grants — the CEO sold 1,500 shares in June at $280.49, well below the current price, and the President sold in May and March. Net insider selling of roughly $924,000 over 90 days is modest relative to the company's size and carries a low significance score.
With earnings due August 5 and recent prints producing small next-day declines averaging around 0.7-1.5%, the setup to watch is whether the recent analyst target upgrades and bullish options positioning prove well-founded — or whether the stock's run past consensus targets has already priced in the good news the company needs to deliver.
See the live data behind this article on ORTEX.
Open PRI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
